Research
Hormonal
Targeted pharmacotherapy with MC4R agonists (specifically setmelanotide) is efficacious and safe for reducing body weight and hunger in patients with specific genetic causes of obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).
If you have been diagnosed with a specific genetic form of obesity (like POMC, LEPR, or BBS deficiency), ask your doctor about setmelanotide. This targeted drug has shown significant weight loss and hunger reduction in clinical trials for your specific genetic profile, unlike standard diets.
GoodSupportsHIGH confidence
The MC4R agonist setmelanotide has demonstrated efficacy and safety for reducing weight and hunger in patients with POMC deficiency caused by biallelic variants in POMC or PCSK1, LEPR deficiency caused by biallelic variants in LEPR, and BBS [106,107].
Why this rating
Supported by Phase 3 clinical trials cited in the review.
Source
Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management
Angela Fitch et al. · Obesity Pillars · 2024
DOI 10.1016/j.obpill.2024.100110
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Traditional nontargeted weight management strategies (lifestyle changes, anti-obesity medications, and metabolic/bariatric surgery) are frequently inadequate for patients with highly penetrant monogenic or syndromic obesity caused by rare genetic variants in the melanocortin-4 receptor (MC4R) pathway.Good
- Metabolic and bariatric surgery (MBS) often results in substantial weight regain in patients with monogenic or syndromic obesity, particularly those with MC4R pathway variants, making it less effective than targeted pharmacotherapy for these groups.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →